港股異動丨微創機器人-B(2252.HK)高開逾10% Mona Lisa前列腺穿刺機器人完成多中心註冊臨牀試驗入組
格隆匯5月3日丨微創機器人-B(2252.HK)高開逾10%,報31.35港元,總市值301億港元。微創機器人昨日宣佈,公司與Biobot Surgical Pte. Ltd.聯合在華成立的合資公司上海介航機器人有限公司所屬產品Mona Lisa前列腺穿刺機器人定位系統("Mona Lisa")完成了全部註冊臨牀試驗入組。此次註冊臨牀試驗由南京大學醫學院附屬鼓樓醫院作為組長單位,聯合西安交通大學第一附屬醫院和蘇北人民醫院共同參研。Mona Lisa在手術過程中運行穩定,操作安全,流程順暢,在手術安全性、學習曲線和穿刺檢出率等方面較傳統手術人工穿刺方式具有明顯優勢,臨牀價值較大。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.